Sonidegib (Odomzo) for the treatment of non-melanoma skin cancer


The drug sonidegib (trade name: Odomzo) has been approved in Germany since February 2018 for adults with locally advanced basal cell carcinoma.

Basal cell carcinoma (basal cell cancer, basalioma), a type of non-melanoma skin cancer, is the most common type of skin cancer. In most cases it develops on the face, the nape of the neck or other parts of the head that are regularly exposed to sun. It is more common in older people. When basal cell carcinoma is discovered, it is usually removed completely in surgery. But sometimes the tumor has already become too big. Radiotherapy is then an option. Sonidegib can be used in patients with basal cell carcinoma who can't have surgery or radiotherapy.

The drug aims to inhibit tumor growth, preventing the disease from progressing.


Sonidegib is taken once daily at the same time in the form of a capsule (200 mg) at least two hours after and at least one hour before a meal. The dosage can be adjusted if side effects occur. This treatment is stopped if severe side effects occur or if the condition gets worse despite treatment.

Other treatments

The standard treatment for people with locally advanced basal cell carcinoma that can't be surgically removed or treated with radiotherapy is the drug vismodegib. Best supportive care (BSC) can also be used. It should be tailored to the patient's individual needs, relieve symptoms such as pain, and improve quality of life.


In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of sonidegib compared with the standard treatments for adults with advanced basal cell carcinoma.

But the manufacturer did not provide any suitable data with which to do the assessment.

More information

This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of this review and the hearings received, the G-BA passed a resolution on the added benefit of sonidegib (Odomzo).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Sonidegib (basal cell carcinoma) – Benefit assessment according to § 35a Social Code Book V. Dossier assessment; Commission A18-10. May 09, 2018. (IQWiG reports; Volume 624).

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Created on May 30, 2018
Next planned update: 2021


Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.